Chargement en cours...
Designer Oncolytic Adenovirus: Coming of Age
The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for oncolytic virotherapy, since it provided unequivocal evidence for the long-touted potential of genetically modified replicating viruses as anti-cancer agents. Whilst T-Vec is promising as a locally delivered virother...
Enregistré dans:
| Publié dans: | Cancers (Basel) |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6025169/ https://ncbi.nlm.nih.gov/pubmed/29904022 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10060201 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|